Jubilant Pharmova Ltd
Nifty 500
Smallcap 250
₹1,025.20
-0.04%
Delayed · cached 15 min
Fair value analysis
JUBLPHARMA
Jubilant Pharmova Ltd
₹1,025.65
Close used for this calculation
₹636.87Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
19/100
Quality radar
Consensus fair value
₹636.87
Above FV▼ -37.9% against the close used
Model range ₹218.24 – ₹893.21
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear₹218.24Fair value₹636.87Bull₹893.21
FairClose
52-week traded range
52W low ₹807.6552W high ₹1,181.20
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading above the consensus fair value
Jubilant Pharmova Ltd closed at ₹1,025.65, 61.0% above the consensus fair value of ₹636.87 drawn from 7 valuation models.
Financial DNA score 19/100 — Weak. P/E of 42.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
₹468.94
-54.3%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=8%, r=10%, tg=3%, n=10yr
Graham Number
₹493.58
-51.9%
√(22.5 × EPS × BVPS)
EPS=25.02, BVPS=432.76 · outside Graham range (P/E 42.1, P/B 2.4) — asset-light, treat as a rough floor
P/E Fair Value
₹893.21
-12.9%
EPS × 35.7x (sector P/E)
EPS=25.02, Sector P/E=35.7x
EV/EBITDA
₹840.63
-18.0%
(EBITDA × 10x − Net Debt) ÷ Shares
EBITDA=17B
Book Value (P/B)
₹218.24
-78.7%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=432.76, ROE=6.5%, g=3%, r=10%
Reverse DCF
₹1,025.65
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 16.8% | Historical: 0%
Margin of Safety
₹463.93
-54.8%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=618.58, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.